This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

About

About

Efficacy
MOAMist MomentsSafety & Dosing

Safety &
Dosing

SafetyDosingFormulary CoverageSavings & Support

Savings
& Support

Savings & Support OptionsPrior Authorization ResourcesMaterialsVideo
Prescribing InformationPatient Information Instructions for UseIndication Press Release
Savings & Support Options
Help your patients access ZAVZPRET with resources like the $0 copay card and with support from our Pfizer Migraine Patient Access Coordinators.
Share this copay card information with your patients
  • Eligible patients with commercial insurance may pay as little as $0 per month*
  • With the ZAVZPRET copay card, eligible commercially insured patients may access ZAVZPRET at no cost while their benefits are being verified†
  • Patients can download and activate a card to get started today by visiting ZAVZPRET.com/savings
Email copay card info
LoadingCopay card
  • Eligible patients with commercial insurance may pay as little as $0 per month*
  • Patients can download and activate a card to get started today by visiting ZAVZPRET.com/savings

*Patients are not eligible to use this card if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico. The offer will be accepted only at participating pharmacies. This offer is not health insurance. No membership fees apply. Pfizer reserves the right to rescind, revoke, or amend this offer without notice. For any questions, please call 1-800-761-1568. For full terms and conditions, visit zavzpret.com/copay-terms or write to Pfizer Inc. at PO Box 29387, Mission, KS 66201.

With support from our Patient Access Coordinators, Pfizer Migraine Patient Access provides important access and coverage resources for providers and for patients prescribed a Pfizer migraine medication, including:

  • Live support by phone for patients and providers
  • Education on the insurance authorization process
  • Information about Pfizer migraine copay programs for eligible, commercially insured patients
Reach out to a Pfizer Migraine Patient Access Coordinator. Call 1-866-222-4183, Monday-Friday between 8 AM-8 PM EST
Visit Pfizer Migraine Patient Access
Loading*Eligible commercially insured patients can, for one time only, access ZAVZPRET at no cost while benefits are being verified for one prescription fill, with a combined maximum of 6 devices total. Insurance coverage must be approved by the payor for patients to continue receiving ZAVZPRET with no out-of-pocket cost. No membership fees. Only available for commercially insured patients. This is not health insurance. The full terms and conditions can be accessed at zavzpret.com/copay-terms.



†As long as coverage is being investigated until the end of 2025. For 1 RX fill only.
Prior Authorization

Accurate and complete prior authorization (PA) submissions may help avoid delayed decisions from the health plan

Pfizer has partnered with CoverMyMeds to help with the PA process and get patients access to ZAVZPRET if prescribed

Sign up to create a CoverMyMeds account, or if you already have an account, submit your PA.

 Sign up Loading Submit PA Loading

Key reminders

  • A patient's full migraine history should be included in the PA submission for ZAVZPRET
  • Inaccurate or inappropriate ICD-10-CM code(s) to describe the patient's migraine diagnosis are a common reason for coverage denials
  • If a health plan denies coverage for ZAVZPRET, the appeals process can be initiated to ask the plan to reconsider its decision

Need help navigating the prior authorization process?                       

We've got tools and resources for you.

 Explore resources Loading
How to prescribe ZAVZPRET nasal spray 10 mg 

Please follow these simple steps below:
Select your patient's local pharmacy in your EMR
Select ICD-10-CM code‡

The codes listed below may be appropriate to include with your request for your patient with migraine. Please refer to an ICD-10-CM resource for additional codes that may be applicable to your patient. 

ICD-10-CM code and description

  • G43, Migraine 
  • G43.0, Migraine without aura 
  • G43.1, Migraine with aura
  • G43.9, Migraine, unspecified
Select quantity

NDC: 0069-3500-02
SIG: Use 1 spray in 1 nostril as needed (PRN).

No more than 1 spray in 24 hours.

EMR=Electronic Medical Record; FDA=U.S. Food and Drug Administration.Codes are provided for informational purposes only. List may not be comprehensive. The healthcare provider is responsible for determining appropriate coding for treatment of their patients. Codes are not intended to encourage or suggest a use that is inconsistent with FDA-approved uses.Savings & Support
Connect with a sales representative

Need additional information, samples, or copay cards? A product representative can assist you.

 Request a representative Loading Check local coverage

Use our formulary lookup tool to discover coverage options in your area.

 Find coverage now Loading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-ZAZ-USA-0611
You are now leaving PfizerPro

You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.
PP-MCL-USA-0367

INDICATION

ZAVZPRET® (zavegepant) is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use: ZAVZPRET is not indicated for the preventive treatment of migraine.

Important Safety InformationContraindications: Hypersensitivity to ZAVZPRET or any of its components.

Warnings and Precautions
Hypersensitivity Reactions: Hypersensitivity reactions, including facial swelling and urticaria, have occurred with ZAVZPRET. If a hypersensitivity reaction occurs, discontinue ZAVZPRET and initiate appropriate therapy.

Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists in the postmarketing setting.

Monitor patients for new-onset hypertension or worsening of pre-existing hypertension and consider whether discontinuation is warranted.

Raynaud’s Phenomenon: Development of Raynaud’s phenomenon and recurrence or worsening of pre-existing Raynaud’s phenomenon have been reported in the postmarketing setting following the use of CGRP antagonists.

If signs or symptoms of Raynaud’s phenomenon develop, discontinue ZAVZPRET. Patients should be evaluated by a healthcare provider if symptoms do not resolve. Patients with a history of Raynaud’s phenomenon should be monitored for, and informed about the possibility of, worsening or recurrence of signs and symptoms. 

Adverse Reactions: Most common adverse reactions (occurring in ≥2% of patients treated with ZAVZPRET and greater than placebo) for ZAVZPRET vs placebo were taste disorders including dysgeusia and ageusia (18% vs 4%), nausea (4% vs 1%), nasal discomfort (3% vs 1%), and vomiting (2% vs <1%).

Drug Interactions: Avoid use with drugs that inhibit or induce OATP1B3 or NTCP transporters. Avoid use of intranasal decongestants; if unavoidable, administer intranasal decongestants at least 1 hour after ZAVZPRET administration.

Use in Specific Populations: Pregnancy: It is not known if ZAVZPRET can harm an unborn baby. Lactation: It is not known whether ZAVZPRET passes into breast milk. Hepatic Impairment: Avoid use in patients with severe hepatic impairment. Renal impairment: Avoid use of ZAVZPRET in patients with creatinine clearance (CLcr) less than 30 mL/min.

Please click here for full Prescribing Information.IndicationZAVZPRET® (zavegepant) is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use: ZAVZPRET is not indicated for the preventive treatment of migraine.

Please see Full Prescribing Information.